Buzz: Biotech stock wiz Jenner raises $100M hedge fund; Novaliq raises $18M; Sarepta licenses DMD intellectual property;

 @FierceBiotech: Still trending: Analysts rank the top 10 blockbuster duds in biopharma. Article | Follow @FierceBiotech

 @JohnCFierce: Everywhere in the world Big Pharma cuts pretty much as it pleases. Sanofi in France? No way. No how. WSJ Report | Follow @JohnCFierce

 @RyanMFierce: In case you missed last night: J&J, Roche and others back platform to bolster translational drug research. Article | Follow @RyanMFierce

> Kris Jenner, the former stock-picking wiz at T. Rowe Price, has raised a $100 million hedge fund to invest in biotech companies and healthcare stocks, according to a report from Bloomberg, which cites sources close to Jenner. "What's distinctive about Kris Jenner is not just his medical and scientific background, but also his ability to connect the dots and see how different information is related," Alexion ($ALXN) CEO Leonard Bell tells Bloomberg. Report

> Germany's Novaliq GmbH, which is focused on the topical application of poorly soluble drugs, today announced the completion of a fifth round of financing of €13.9m ($18.1m). Release

> Sarepta Therapeutics ($SRPT) has inked a $7 million licensing pact with the University of Western Australia covering the IP on potential exon-skipping drugs for Duchenne muscular dystrophy. Release

> Shares of Infinity Pharmaceuticals ($INFI) declined 4% after the company priced a secondary offering. Story

Medical Device News

 @FierceMedDev: New radiation therapy companion Dx in the works. More | Follow @FierceMedDev

 @MarkHFierce: Roche's diagnostics division sales fell flat in Q1. Dx tests sold well, but its diabetes arm tanked. Story | Follow @MarkHFierce

 @DamianFierce: We read the FDA's budget request so you don't have to: The agency wants an 11% raise for device approvals. Article | Follow @DamianFierce

> FDA slaps most serious label on Stryker's surgical recall. Article

> Doctor accused of performing unnecessary stent procedures begins civil trial. Item

Pharma News

 @FiercePharma: Roche's Avastin delivered in the first quarter, too: 11% growth, to 1.53B francs, almost back to 2010 levels. | Follow @FiercePharma

 @EricPFierce: FDA did 813 inspections in 62 countries last year, but it says it needs even more money to keep up. Story | Follow @EricPFierce

> President's budget takes a big bite out of Medicare drug spending. News

> Pharma reps aren't talking about drug risks, study finds. Report

Pharma Manufacturing News

> FDA nails Pfizer plant for contaminated Torisel diluent. News

> Sanofi plant ramps up malaria treatment with cutting-edge technology. Article

> FDA budget would expand China office. Story

> Hamburg to face Congress again over compounding lapses. Report

> Mylan Napa plant to close by year-end. Article

Vaccines News

> U.S. works with Inovio in prep for bioterrorism vaccinations. Article

> China expects H7N9 vaccine in 7 months. Item

> Ovarian cancer vax makes good start on long slog to approval. Story

> Negative vaccine views spread like viruses on Twitter. Article

> H7N9 an early test for revised U.S. pandemic preparations. Report

And Finally… Investigators at Johns Hopkins say that a protein called EPAC2, long viewed as relatively unimportant in the development of diabetes, is actually an important regulator of insulin. Release


Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.